A phase 1 study of RT 110
Latest Information Update: 18 Nov 2022
Price :
$35 *
At a glance
- Drugs RT-110 (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions
- 18 Nov 2022 New trial record
- 10 Nov 2022 According to a Rani Therapeutics media release, this trial is expected to begin in 2023.